Combination therapy response biomarkers of colorectal cancer

Posted in the Colon Cancer Forum


Madison, WI

#1 Feb 21, 2012
According to this recent US patent application, high pretreatment plasma YKL-40 and serum YKL-40 levels were prognostic biomarkers of short overall survival in two independent studies of patients with metastatic colorectal cancer treated with third-line cetuximab in combination with irinotecan. Details:

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Colon Cancer Discussions

Title Updated Last By Comments
Less invasive may be best way (Jan '14) Apr '14 Deb 5
City of Toronto refuses to pay for funeral of u... (Jan '14) Jan '14 wild child 8
The 10 commandments of cancer prevention (May '09) Nov '13 One for all All f... 5
FDA approves Amgen colon cancer drug Vectibix (Feb '07) Nov '13 yoram 2
BLOG: Farrah Fawcett's Cancer Battle Raising Qu... (May '09) Sep '13 bud_schmones 6
Antidepressant enhances chemotherapy drug (Dec '08) Sep '13 Dashawn 2
In colon cancer drug study, more wasna t better (Feb '09) Sep '13 Ezekiel 5
Enter and win $5000

Colon Cancer People Search

Addresses and phone numbers for FREE